GALAPAGOS NV/S (GLPG) Upgraded to “Buy” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a hold rating to a buy rating in a research note released on Friday morning.

Several other research firms have also issued reports on GLPG. Credit Suisse Group raised shares of GALAPAGOS NV/S from a neutral rating to an outperform rating in a research report on Thursday, December 13th. Morgan Stanley raised their price objective on shares of GALAPAGOS NV/S from $127.00 to $131.00 and gave the stock an overweight rating in a report on Monday, November 5th. ValuEngine raised shares of GALAPAGOS NV/S from a buy rating to a strong-buy rating in a report on Saturday, November 10th. Raymond James initiated coverage on shares of GALAPAGOS NV/S in a report on Wednesday, November 14th. They set a strong-buy rating and a $157.00 price objective for the company. Finally, Zacks Investment Research lowered shares of GALAPAGOS NV/S from a buy rating to a hold rating in a report on Tuesday, November 13th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of Buy and a consensus target price of $122.00.

NASDAQ:GLPG traded down $2.17 during mid-day trading on Friday, hitting $104.45. The company’s stock had a trading volume of 70,643 shares, compared to its average volume of 85,830. GALAPAGOS NV/S has a fifty-two week low of $85.00 and a fifty-two week high of $122.28. The firm has a market capitalization of $5.41 billion, a PE ratio of -39.56 and a beta of 1.74.

GALAPAGOS NV/S (NASDAQ:GLPG) last posted its quarterly earnings results on Friday, October 26th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.70. GALAPAGOS NV/S had a negative net margin of 30.65% and a negative return on equity of 7.66%. The firm had revenue of $119.99 million during the quarter, compared to analyst estimates of $82.15 million. Equities research analysts expect that GALAPAGOS NV/S will post -1.74 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Financial Gravity Wealth Inc. boosted its stake in GALAPAGOS NV/S by 64.1% in the third quarter. Financial Gravity Wealth Inc. now owns 2,261 shares of the biotechnology company’s stock valued at $225,000 after acquiring an additional 883 shares during the last quarter. Bank of America Corp DE boosted its stake in GALAPAGOS NV/S by 11.7% in the second quarter. Bank of America Corp DE now owns 9,758 shares of the biotechnology company’s stock valued at $899,000 after acquiring an additional 1,025 shares during the last quarter. Macquarie Group Ltd. boosted its stake in GALAPAGOS NV/S by 13.5% in the second quarter. Macquarie Group Ltd. now owns 9,865 shares of the biotechnology company’s stock valued at $909,000 after acquiring an additional 1,170 shares during the last quarter. Putnam Investments LLC boosted its stake in GALAPAGOS NV/S by 8.5% in the second quarter. Putnam Investments LLC now owns 22,682 shares of the biotechnology company’s stock valued at $2,091,000 after acquiring an additional 1,770 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in GALAPAGOS NV/S in the third quarter valued at approximately $256,000. 18.13% of the stock is owned by institutional investors.

About GALAPAGOS NV/S

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Read More: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Village Farms International  Trading 20.4% Higher
Village Farms International Trading 20.4% Higher
Enablence Technologies  Trading Down 16.7%
Enablence Technologies Trading Down 16.7%
Q4 2019 EPS Estimates for Citizens Financial Group Inc  Lowered by Wedbush
Q4 2019 EPS Estimates for Citizens Financial Group Inc Lowered by Wedbush
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
Trevali Mining  Price Target Lowered to C$0.60 at National Bank Financial
Trevali Mining Price Target Lowered to C$0.60 at National Bank Financial


Leave a Reply

 
© 2006-2019 Zolmax.